Tuberculosis vaccines: Time for a global strategy

Science Translational Medicine

Volumn 7, Issue 276, 2015, Pages

  Kaufmann, Stefan H E ^a   Evans, Thomas G ^b   Hanekom, Willem A ^c  

^a MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

^b AERAS   (United States)

^c BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

AGE DISTRIBUTION; ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; ECONOMIC ASPECT; FINANCE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE COST; HEALTH CARE NEED; HEALTH CARE POLICY; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOMODULATION; INCIDENCE; INFECTION PREVENTION; LUNG TUBERCULOSIS; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; SHORT SURVEY; CLINICAL TRIAL (TOPIC); COST; ECONOMICS; IMMUNOLOGY; INTERNATIONAL COOPERATION;

CLINICAL TRIALS AS TOPIC; COSTS AND COST ANALYSIS; HUMANS; INTERNATIONALITY; TUBERCULOSIS VACCINES;

EID: 84923923821     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aaa4730     Document Type: Short Survey

References (10)

1. G. M. Knight, U. K. Griffiths, T. Sumner, Y. V. Laurence, A. Gheorghe, A. Vassall, P. Glaziou, R. G. White, Impact and cost-eff ectiveness of new tuberculosis vaccines in low- and middle-income countries. Proc. Natl. Acad. Sci. U.S.A. 111, 15520-15525 (2014).
2. S. H. Kaufmann, Fact and fiction in tuberculosis vaccine research: 10 years later. Lancet Infect. Dis. 11, 633-640 (2011).
3. M. D. Tameris, M. Hatherill, B. S. Landry, T. J. Scriba, M. A. Snowden, S. Lockhart, J. E. Shea, J. B. McClain, G. D. Hussey, W. A. Hanekom, H. Mahomed, H. McShane, MVA85A 020 Trial Study Team, Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: A randomised, placebo-controlled phase 2b trial. Lancet 381, 1021-1028 (2013).
4. S. H. Kaufmann, S. K. Parida, Changing funding patterns in tuberculosis. Nat. Med. 13, 299-303 (2007).
5. J. Weiner, J. Maertzdorf, S. H. Kaufmann, The dual role of biomarkers for understanding basic principles and devising novel intervention strategies in tuberculosis. Ann. N. Y. Acad. Sci. 1283, 22-29 (2013).
6. G. Walzl, K. Ronacher, W. Hanekom, T. J. Scriba, A. Zumla, Immunological biomarkers of tuberculosis. Nat. Rev. Immunol. 11, 343-354 (2011).
7. B. F. Haynes, M. J. McElrath, Progress in HIV-1 vaccine development. Curr. Opin. HIV AIDS 8, 326-332 (2013).
8. B. M. Kagina, B. Abel, T. J. Scriba, E. J. Hughes, A. Keyser, A. Soares, H. Gamieldien, M. Sidibana, M. Hatherill, S. Gelderbloem, H. Mahomed, A. Hawkridge, G. Hussey, G. Kaplan, W. A. Hanekom, other members of the South African Tuberculosis Vaccine Initiative, Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns. Am. J. Respir. Crit. Care Med. 182, 1073-1079 (2010).
9. R. Rustomjee, S. Lockhart, J. Shea, P. B. Fourie, Z. Hindle, G. Steel, G. Hussey, A. Ginsberg, M. J. Brennan, Novel licensure pathways for expeditious introduction of new tuberculosis vaccines: A discussion of the adaptive licensure concept. Tuberculosis (Edinb.) 94, 178-182 (2014).
10. S. H. Kaufmann, Tuberculosis vaccines: Time to think about the next generation. Semin. Immunol. 25, 172-181 (2013).